NK Cells in Cancer Immunotherapy: Successes and Challenges explains the latest immunotherapeutic strategies, focusing on NK cells to allow the best and precise combination treatments to cancer patients. The book provides existing background knowledge in the field of immunotherapy and discusses future areas of research required to carry out cutting-edge, validated therapies. Chapters cover advances in immunotherapeutic strategies, in particular, the use of NK cells with and without T-cell therapy in the treatment of cancer. The book is a valuable resource for cancer researchers, oncologists, graduate students and those interested in learning more about novel strategies to treat cancer patients.
Immunotherapy is fast becoming the method of choice for cancer therapy. Although remarkable advances have been made in the field of immunotherapy, there are significant challenges and difficulties ahead since many of the current immunotherapeutic strategies do not provide long-lasting treatment strategies, and therefore are not very effective.
1. NK Cells in Cancer Immunotherapy: Successes and Challenges - p. Page i 2. Cover - p. Page i 3. Front Matter - p. Page i 4. Table of Contents - p. Page iv 5. Copyright - p. Page v 6. Cover Image Insert - p. Page vi 7. Aims and Scope of Series “Breaking Tolerance to Anti-Cancer Cell-Mediated Immunotherapy” - p. Page vii 8. About the Series Editor - p. Page vii 9. Aims and Scope of Volume - p. Page viii 10. About the Volume Editors - p. Page ix 11. Preface—Cellular immunotherapies: Evolution from laboratory studies to effective human therapies - p. Page xi 12. Contributors - p. Page xiv 13. List of Illustrations - p. Page xvii 14. List of Tables - p. Page xviii 15. Chapter 1 : Multifaceted nature of natural killer cells: Potential mode of interaction and shaping of stem cells - p. Page xviii 16. Chapter 2 : Reversing the NK inhibitory tumor microenvironment by targeting suppressive immune effectors - p. Page 17 17. Chapter 3 : Natural killer cells as immunotherapeutic effectors for solid tumors - p. Page 54 18. Chapter 4 : Targeting NKG2D/NKG2D ligand axis for cancer immunotherapy - p. Page 76 19. Chapter 5 : Chimeric antigen receptor-modified cells for the treatment of solid tumors: First steps in a thousand-mile march - p. Page 92 20. Chapter 6 : Tumor-infiltrating lymphocyte (TIL) therapy - p. Page 119 21. Chapter 7 : Biology and status of chimeric antigen receptor-engineered T cell therapy - p. Page 145 22. Chapter 8 : Optimization of production for cell therapies - p. Page 162 23. Chapter 9 : Lymphodepletion and cellular immunotherapy - p. Page 178 24. Chapter 10 : Imaging the immune cell in immunotherapy - p. Page 191 25. Chapter 11 : Radiologic assessment of tumor response to immunotherapy and its complications - p. Page 226 26. Chapter 12 : Novel cell delivery systems: Intracranial and intrathecal - p. Page 258 27. Chapter 13 : Diagnostic methods to assess the numbers, phenotype, and function of primary and engineered NK cells: Methods to predict prognosis and treatment outcome - p. Page 276 28. Chapter 14 : Combination of NK cell immunotherapy with chemotherapy and radiation enhances NK cell therapy and provides improved prognosis in cancer patients and in humanized BLT mouse model system - p. Page 295 29. Chapter 15 : Combining oncolytic viruses with immune cell therapy as treatments for cancer: OV, CAR T-cell, and NK combinations - p. Page 315 30. Chapter 16 : Natural killer cells in the treatment of glioblastoma: Diverse antitumor functions and potential clinical applications - p. Page 332 31. Chapter 17 : Immunotherapy using CAR T: What we have learned from trials and where we are heading - p. Page 359 32. Chapter 18 : NKT cell: Success and promises in transplantation and immunotherapy - p. Page 383 33. Chapter 19 : Tumor-infiltrating lymphocytes: Prognostic considerations and current trials as adoptive cell therapy - p. Page 396 34. Chapter 20 : Molecular remission using personalized low-dose immunotherapy with minimal toxicities for poor prognosis hematological and solid tumor cancers - p. Page 417 35. Index - p. Page 451
NK Cells in Cancer Immunotherapy: Successes and Challenges explains the latest immunotherapeutic strategies, focusing on NK cells to allow the best and precise combination treatments to cancer patients. The book provides existing background knowledge in the field of immunotherapy and discusses future areas of research required to carry out cutting-edge, validated therapies. Chapters cover advances in immunotherapeutic strategies, in particular, the use of NK cells with and without T-cell therapy in the treatment of cancer. The book is a valuable resource for cancer researchers, oncologists, graduate students and those interested in learning more about novel strategies to treat cancer patients.
Immunotherapy is fast becoming the method of choice for cancer therapy. Although remarkable advances have been made in the field of immunotherapy, there are significant challenges and difficulties ahead since many of the current immunotherapeutic strategies do not provide long-lasting treatment strategies, and therefore are not very effective.
1. NK Cells in Cancer Immunotherapy: Successes and Challenges - p. Page i 2. Cover - p. Page i 3. Front Matter - p. Page i 4. Table of Contents - p. Page iv 5. Copyright - p. Page v 6. Cover Image Insert - p. Page vi 7. Aims and Scope of Series “Breaking Tolerance to Anti-Cancer Cell-Mediated Immunotherapy” - p. Page vii 8. About the Series Editor - p. Page vii 9. Aims and Scope of Volume - p. Page viii 10. About the Volume Editors - p. Page ix 11. Preface—Cellular immunotherapies: Evolution from laboratory studies to effective human therapies - p. Page xi 12. Contributors - p. Page xiv 13. List of Illustrations - p. Page xvii 14. List of Tables - p. Page xviii 15. Chapter 1 : Multifaceted nature of natural killer cells: Potential mode of interaction and shaping of stem cells - p. Page xviii 16. Chapter 2 : Reversing the NK inhibitory tumor microenvironment by targeting suppressive immune effectors - p. Page 17 17. Chapter 3 : Natural killer cells as immunotherapeutic effectors for solid tumors - p. Page 54 18. Chapter 4 : Targeting NKG2D/NKG2D ligand axis for cancer immunotherapy - p. Page 76 19. Chapter 5 : Chimeric antigen receptor-modified cells for the treatment of solid tumors: First steps in a thousand-mile march - p. Page 92 20. Chapter 6 : Tumor-infiltrating lymphocyte (TIL) therapy - p. Page 119 21. Chapter 7 : Biology and status of chimeric antigen receptor-engineered T cell therapy - p. Page 145 22. Chapter 8 : Optimization of production for cell therapies - p. Page 162 23. Chapter 9 : Lymphodepletion and cellular immunotherapy - p. Page 178 24. Chapter 10 : Imaging the immune cell in immunotherapy - p. Page 191 25. Chapter 11 : Radiologic assessment of tumor response to immunotherapy and its complications - p. Page 226 26. Chapter 12 : Novel cell delivery systems: Intracranial and intrathecal - p. Page 258 27. Chapter 13 : Diagnostic methods to assess the numbers, phenotype, and function of primary and engineered NK cells: Methods to predict prognosis and treatment outcome - p. Page 276 28. Chapter 14 : Combination of NK cell immunotherapy with chemotherapy and radiation enhances NK cell therapy and provides improved prognosis in cancer patients and in humanized BLT mouse model system - p. Page 295 29. Chapter 15 : Combining oncolytic viruses with immune cell therapy as treatments for cancer: OV, CAR T-cell, and NK combinations - p. Page 315 30. Chapter 16 : Natural killer cells in the treatment of glioblastoma: Diverse antitumor functions and potential clinical applications - p. Page 332 31. Chapter 17 : Immunotherapy using CAR T: What we have learned from trials and where we are heading - p. Page 359 32. Chapter 18 : NKT cell: Success and promises in transplantation and immunotherapy - p. Page 383 33. Chapter 19 : Tumor-infiltrating lymphocytes: Prognostic considerations and current trials as adoptive cell therapy - p. Page 396 34. Chapter 20 : Molecular remission using personalized low-dose immunotherapy with minimal toxicities for poor prognosis hematological and solid tumor cancers - p. Page 417 35. Index - p. Page 451
